MedTrace Logo

The Effect of Salmeterol on Eosinophil (EOS) Function

NCT00214019 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-11-21

Study results available
· View outcomes & findings →

Summary

This study is designed to test the hypothesis that salmeterol use, and not fluticasone use or the combination treatment with fluticasone and salmeterol, is associated with a greater number of sputum eosinophils following antigen challenge and, under these circumstances, the migrating peripheral blood eosinophils are less adherent.

Conditions

  • Allergic Asthma

Interventions

DRUG

salmeterol

salmeterol diskus 50 mcg twice per day

DRUG

Fluticasone

placebo diskus, fluticasone MDI 88 mcg twice per day

DRUG

Placebo

placebo diskus

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • William Busse, MD · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214019 on ClinicalTrials.gov